Neoisoliquiritigenin inhibits tumor progression by targeting GRP78- β-catenin signaling in breast cancer.

In this study, we found that GRP78 could promote breast cancer initiation and progression, and higher expression of GRP78 indicated poorer state of breast cancer patients, suggesting that GRP78 was a significant oncogene with the potential to be a novel biomarker and target in clinical investigation. Also, according to the analysis of molecular docking, we found a derivative of Isoliquiritigenin, Neoisoliquiritigenin (NISL), showed a vital inhibitory effect on breast cancer through direct binding to GRP78 to regulate β-catenin pathway. Taken together, this study not only highlight the significance of GRP78 in breast cancer development via β-catenin signaling but also suggest NISL as a natural candidate to inhibit breast cancer by targeting GRP78. PMID: 28914191 [PubMed - as supplied by publisher]
Source: Current Cancer Drug Targets - Category: Cancer & Oncology Authors: Tags: Curr Cancer Drug Targets Source Type: research